Saudi Arabia caps tirzepatide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger in 2025
Page 2 of 10 of this archive, newest first.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Mexico caps liraglutide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
South Korea caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Mexico declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The dose that got you here and the dose that keeps you here
What the labels permit, what clinicians do, and the size of the gap between them.
Why people actually stop, in the order they actually stop
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
Nigeria caps liraglutide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Denmark declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Canada caps liraglutide prescribing to 4 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Netherlands declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The named comparison we promised two years ago
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Mexico declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Blind duplicates: what happens when a laboratory does not know it is being watched
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Switzerland declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Randomised withdrawal is the cleanest design in this field and the least discussed
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Spain caps liraglutide prescribing to 24 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Netherlands declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.